Calcium player invests in nutra & pharma lab
Omya said it wanted to work more independently as previous collaborations in nutraceutical and pharmaceutical applications had presented issues around ownership of intellectual property.
“With its own lab, Omya can react to market needs much faster now and ensures legal certainty for both itself and its customers, which is a prerequisite for the company to be able to sell its products without restrictions,” the firm said.
132-year-old Omya said the facility that houses a wet lab for NPD, a dry lab for ‘granulation, tabletting and performance analysis’ as well as storage and office space is fitted with “fluid-bed technology, a roller compactor and a rotary tablet press”.
The company said ongoing projects around natural minerals and excipients “that allows granules and tablets with high levels of mechanical strength and fast disintegration times” would benefit from the new site.
Stefan Lander, VP of consumer goods, said the firm was working at “developing new structured minerals that are tailor-made for specific applications or optimising existing products to meet the changing needs of the industry.”
One result would be “shorter times-to-market for pharmaceutical and nutraceutical products.”